Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Home Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

/ Publications

Share the Post

About the Author

Related Posts

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations
Baiteng Zhao, PhD
Phase 2, Multicenter, Global, Open-Label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)
Read More
Richard Maroun, JD
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Comments

Comments are closed.